HYDERABAD, India & BASEL, Switzerland & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories SA, wholly-owned subsidiary of Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced that it has entered into a definitive agreement to acquire the U.S. generic prescription product portfolio of Salisbury, Australia, based Mayne Pharma Group Limited (ASX: MYX). Read more >
- The BUZZ / News
- Publications
- MarketplaceCompoundingContamination ControlDelivery & ShippingDistributionFacilitiesFinanceManufacturingMerchandisingPatient CarePRACTICE SETTINGSProfessional DevelopmentProfessional ServicesSoftware
Business Management, Operations, ERP
Clinical Monitoring, Surveillance, Insights
Controlled Substance Reporting
Clinical Decision Support, Point of Care Reference, Dosing, DUR
Drug Diversion Monitoring, Diversion Prevention
Error Prevention, Drug Validation
eMAR, EMR, EHR, Bedside Verification
Formulary Management
IV Workflow Management
Long-Term Care Operation Management
Medication Inventory Management & Procurement
Pharmacy Management Systems, Workflow
Stewardship Resources (Antibiotic, Opioid, etc)Unit DoseWorkflow - Multimedia Content
- Career Center
- Market Intelligence
- Company
- Chaintel
